Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | CCKBR | P32239 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | RECQL | P46063 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 8/20 | 0.58 |
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperacillin SCHEMBL27343970 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL10477435 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL13788683 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL13788684 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL11908507 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL24437361 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL3233001 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL4486297 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL14506140 | 1.00 | MEN1 (0.77) | MEN1KMT2ACCKBRLMNAKDM4E | |
| Piperacillin SCHEMBL41302 | 0.99 | MEN1 (0.76) | MEN1KMT2ACCKBRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35100 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747395-A1 | A KIT FOR IDENTIFYING BACTERIA AND DETERMINING ANTIBIOTIC SENSITIVITY | Diagopreutic Private Limited (IN) | 2026-05-27 | — | — | EP | claimed |
| US-12636268-B2 | CXCL8 inhibitors for use in the treatment of COVID-19 | DOMPE' FARMACEUTICI SPA (IT) | 2026-05-26 | — | — | US | claimed |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| EP-4041275-B1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | FARSIGHT MEDICAL TECH SHANGHAI CO LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4743153-A1 | MEDICAL SYSTEMS FOR TREATING CONDITIONS AND DISEASES OF THE PATIENT'S BODY CAVITIES | UTT Urine Topical Treatment Ltd (IL) | 2026-05-20 | — | — | EP | claimed |
| CN-122036889-A | Cyclized antibacterial peptide CycP-1 of targeted multi-drug resistant klebsiella pneumoniae, composition and application thereof | 湖北江夏实验室 | 2026-05-15 | — | — | CN | claimed |
| CN-122031784-A | Preparation method of microporous polylactic acid drug-loaded coating | 浙江药科职业大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | claimed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | claimed |
| US-4452796-A | ANTIBIOTICS | PFIZER INC. (US) | 1984-06-05 | — | — | US | claimed |
| EP-0108295-A1 | Oral dosage form | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-16 | — | — | EP | claimed |
| US-4427678-A | 6-Aminomethylpenicillanic acid 1,1-dioxide derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1984-01-24 | — | — | US | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | claimed |
| EP-0004925-B1 | SYNERGISTIC MIXTURES OF ANTIBIOTICS AND PROCESS FOR THEIR PRODUCTION | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | claimed |
| EP-0026409-A1 | Combinations of active ingredients, pharmaceutical preparations, as well as their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-04-08 | — | — | EP | claimed |
| EP-0004925-A1 | Synergistic mixtures of antibiotics and process for their production | CIBA-GEIGY AG (CH) | 1979-10-31 | — | — | EP | claimed |